{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:22:31Z","timestamp":1792891351552,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson Innovative Medicine, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40258-024-00897-x","type":"journal-article","created":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T07:01:46Z","timestamp":1720854106000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-2578","authenticated-orcid":false,"given":"Maryia","family":"Zhdanava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Pesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Schwartzbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zia","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Souayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,13]]},"reference":[{"issue":"10","key":"897_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"key":"897_CR2","volume":"2012","author":"A Jayam Trouth","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, et al. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012: 874680.","journal-title":"Autoimmune Dis."},{"issue":"17 Supplement 2","key":"897_CR3","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1212\/WNL.0000000000202945","volume":"100","author":"E Rodrigues","year":"2023","unstructured":"Rodrigues E, Umeh E, Uday A, et al. Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis (S19.007). Neurology. 2023;100(17 Supplement 2):2994.","journal-title":"Neurology"},{"issue":"11","key":"897_CR4","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"4","key":"897_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"897_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"1","key":"897_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14195","volume":"1452","author":"XJ Cai","year":"2019","unstructured":"Cai XJ, Li ZW, Xi JY, et al. Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Ann N Y Acad Sci. 2019;1452(1):18\u201333.","journal-title":"Ann N Y Acad Sci"},{"key":"897_CR8","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2019","unstructured":"Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2019;10:3052.","journal-title":"Front Immunol"},{"issue":"10","key":"897_CR9","volume":"14","author":"AS Zubair","year":"2022","unstructured":"Zubair AS, Roy B, Baehring JM, et al. Myasthenia gravis in the setting of immune checkpoint inhibitor therapy: practical considerations and opinion-based approach to acute management. Cureus. 2022;14(10): e30638.","journal-title":"Cureus."},{"issue":"6","key":"897_CR10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Marano A, Krueger A, et al. Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve. 2011;44(6):907\u201311.","journal-title":"Muscle Nerve"},{"issue":"3","key":"897_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.22327","volume":"45","author":"JT Guptill","year":"2012","unstructured":"Guptill JT, Sharma BK, Marano A, et al. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve. 2012;45(3):363\u20136.","journal-title":"Muscle Nerve"},{"key":"897_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","volume":"12","author":"G Phillips","year":"2021","unstructured":"Phillips G, Abreu C, Goyal A, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2021;12: 809999.","journal-title":"Front Neurol"},{"issue":"7","key":"897_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, et al. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715\u201328.","journal-title":"Pharmacoeconomics"},{"issue":"445","key":"897_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120531","volume":"15","author":"A Ting","year":"2023","unstructured":"Ting A, Story T, Lecomte C, et al. A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J Neurol Sci. 2023;15(445): 120531.","journal-title":"J Neurol Sci"},{"issue":"6","key":"897_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68(6):797\u2013805.","journal-title":"Ann Neurol"},{"issue":"1","key":"897_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","volume":"2","author":"SM Lundberg","year":"2020","unstructured":"Lundberg SM, Erion G, Chen H, et al. From local explanations to global understanding with explainable AI for trees. Nat Mach Intell. 2020;2(1):56\u201367.","journal-title":"Nat Mach Intell."},{"key":"897_CR17","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1165.1000227","author":"KP Vatcheva","year":"2016","unstructured":"Vatcheva KP, Lee M, McCormick JB, et al. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale). 2016. https:\/\/doi.org\/10.4172\/2161-1165.1000227.","journal-title":"Epidemiology (Sunnyvale)."},{"key":"897_CR18","unstructured":"Yu L, Liu H, editors. Feature selection for high-dimensional data: a fast correlation-based filter solution. International Conference on Machine Learning; 2003; Washington, DC."},{"issue":"3","key":"897_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/widm.1301","volume":"9","author":"P Probst","year":"2019","unstructured":"Probst P, Wright MN, Boulesteix A. Hyperparameters and tuning strategies for random forest. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(3): e1301.","journal-title":"Wiley Interdiscip Rev Data Min Knowl Discov."},{"key":"897_CR20","unstructured":"Lundberg SM, Lee S, editors. A unified approach to interpreting model predictions. Advances in Neural Information Processing Systems 2017: Curran Associates, Inc."},{"issue":"7","key":"897_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136.","journal-title":"Am J Epidemiol"},{"key":"897_CR22","unstructured":"Elixhauser A SC, Kruzikas. D. HCUP comorbidity software. Agency for Healthcare Research and Quality, Rockville, MD.; 2015. Available from: https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download"},{"issue":"2","key":"897_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1257\/jep.31.2.87","volume":"31","author":"S Mullainathan","year":"2017","unstructured":"Mullainathan S, Spiess J. Machine learning: an applied econometric approach. J Econ Perspect. 2017;31(2):87\u2013106.","journal-title":"J Econ Perspect"},{"key":"897_CR24","unstructured":"National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Bethesda, MD: National Institutes of Health (NIH); [updated 21 November, 2023; cited 19 January 2024]. Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/myasthenia-gravis#"},{"issue":"4","key":"897_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","volume":"11","author":"M Mahic","year":"2022","unstructured":"Mahic M, Bozorg AM, DeCourcy JJ, et al. Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey. Neurol Ther. 2022;11(4):1535\u201351.","journal-title":"Neurol Ther."},{"issue":"1","key":"897_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22(1):17\u201323.","journal-title":"Eur J Neurol"},{"issue":"2","key":"897_CR27","first-page":"132","volume":"5","author":"M Cojocaru","year":"2010","unstructured":"Cojocaru M, Cojocaru IM, Silosi I. Multiple autoimmune syndrome. Maedica (Bucur). 2010;5(2):132\u20134.","journal-title":"Maedica (Bucur)."},{"issue":"4","key":"897_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1055\/s-2001-19414","volume":"21","author":"RM Pascuzzi","year":"2001","unstructured":"Pascuzzi RM. Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. Semin Neurol. 2001;21(4):425\u201340.","journal-title":"Semin Neurol"},{"issue":"12","key":"897_CR29","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978\u201380.","journal-title":"Neurology"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00897-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00897-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:25:04Z","timestamp":1724408704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00897-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,13]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00897-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,13]]},"assertion":[{"value":"11 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen Scientific Affairs, LLC, a Johnson & Johnson company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.Z., P.B., S.S., D.P., M.L., and P.L. are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, a Johnson & Johnson company, which funded the development and conduct of this study and manuscript. J.P., Q.C., and Z.C. are employees and stockholders of Janssen Scientific Affairs, LLC, a Johnson & Johnson company. NS has no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"M.Z., P.B., S.S., D.P., M.L., and P.L. contributed to study conception and design, collection and assembly of data, and data analysis and interpretation. J.P., Q.C., Z.C., and N.S. contributed to study conception and design and data analysis and interpretation. All authors reviewed and approved the final content of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The data that support the findings of this study are available from IQVIA. Restrictions apply to the availability of these data, which were used under license for this study. Data are available from the authors with the permission of IQVIA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Data are de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Per HIPAA, there are no restrictions on the use or disclosure of de-identified health information (Title 45 of CFR, Part 164.502(d)(2), 164.514(a) and (b)). eNo review by an institutional review board was required per Title 45 of CFR, Part 46.104(d)(4)\u00a0because the data were de-identified.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from Patients\/Participants)"}},{"value":"All analyses were conducted using SAS Enterprise Guide 7.1 (SAS Institute, Cary, NC). The SAS programs are proprietary materials of Analysis Group, Inc.; therefore, restrictions apply to the access of these codes, which cannot be made available publicly.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Part of the material in this manuscript was presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 held 16\u201319 October 2023, in Orlando, FL, as poster presentation.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Presentation"}}]}}